15 Heart failure in cancer patients: management through ONCO-cardiology

Heart failure (HF) is one of the most dreaded complications of cancer therapy that can significantly impact morbidity and mortality. With new treatment modalities in oncology with potential cardiotoxicity and a high prevalence of cardiovascular disease in cancer patients, the risk of developing HF is significantly increased. HF can occur acutely during chemotherapy administration, or it can manifest years after the completion of cancer treatment. Cancer survivors may develop chemotherapy-induced HF several years after completing anthracycline-based treatment. Timely diagnosis, intervention and surveillance of cancer patients while receiving treatment and after survivorship are critical in the prevention and management of left ventricular dysfunction that can lead to HF. Cancer patients with concurrent HF experience complex clinical management issues that require a multidisciplinary approach and a close collaboration among oncologists, cardiologists, and the health care team. A new discipline of Onco-Cardiology has evolved to address the cardiovascular needs of patients with cancer. The collaboration between oncologists and cardiologists can optimise patients’ chances of receiving successful cancer therapy while avoiding the morbidity and mortality associated with HF.
Source: Heart Asia - Category: Cardiology Authors: Tags: APAHFF Abstracts 2017 Source Type: research